R&D Portfolio Update February 2019: DNDi Chagas disease programme

A Phase II study of new benznidazole regimens was completed in 2018 with results coming in 2019. A Phase II study of fexinidazole, a new drug being tested for Chagas, completed patient recruitment in 2018. New diagnosis and treatment access projects were launched in Guatemala and Brazil, and the project in Colombia showed major increases in people tested in pilot areas.

Wellcome commits £10 million to DNDi to develop new generation of oral drugs to treat leishmaniasis

London/Geneva – 5 February 2019
Wellcome has committed over £10 million to DNDi to develop new treatments for leishmaniasis, one of the world’s most devastating parasitic diseases. The three-year partnership will enable DNDi and Wellcome to develop new combinations of entirely new, all-orally acting chemical entities, through a joint strategy that also harnesses the strengths of the pharmaceutical and biotechnology industries, academia, and product development partnerships.

CTDDR 2019

20-23 February 2019
Lucknow, India

  • Presentation of the development of DNDI-0690, a new clinical candidate for visceral leishmaniasis

Keystone Conference 2018

21st Century Drug Discovery and Development for Global Health

17-20 October 2018
Berlin, Germany

  • Nathalie Strub-Wourgaft, NTD Director – presentation on the new therapies for sleeping sickness
  • Charles Mowbray, Discovery Director – presentation on new orally active treatments for leishmaniasis

National Regulatory Conference (NRC) 2018

2-4 October 2018
Selangor, Malaysia

  • Marion Laumonier, Head of Regulatory Affairs – presentation on registration pathways and forum discussion on collaborative efforts between regulators and stakeholders